Anti-VEGF

Treating Proliferative Diabetic Retinopathy

Whether it’s with anti-VEGF or PRP, patients’ outcomes may depend on their access to care and ability to follow up.
01/10/2023

An Update on the Anti-VEGF Biosimilar Pipeline

Biosimilars for diseases like AMD and diabetic retinopathy could possibly offer patients effective, less-costly options.
01/10/2023

Weathering the Storm of Neovascular Glaucoma

By the time your patients complain of symptoms, it may be too late. An expert shares how to manage this disease.
12/13/2022

Phase III Trials in Wet AMD—What’s Next?

A look at the drugs and devices closest to the clinical-trial finish line in the United States.
11/05/2020

Debating Anti-VEGF Injections

Here’s why comprehensive ophthalmologists shouldn’t inject—or why they should.
09/09/2020

An Extra Push for Wet AMD Patients

Conventional and not-so-conventional treatments to consider when these patients don’t respond to initial anti-VEGF therapy.
08/10/2020